Tag #Drug Approvals

Showing 1 to 3 of 3 results

theglobeandmail.com

🌐 85% Global Worthiness

Sep 5, 01:18

Health Canada vows to expedite biosimilar drug approvals to reduce costs

Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.

Health Canada vows to expedite biosimilar drug approvals to reduce costs

Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How are these delays impacting drugmakers and healthcare payers?

Delays threaten the financial viability of biosimilar drugmakers, potentially deterring future investments in Canada. Simultaneously, the delays force public drug plans to continue paying for more expensive brand-name biologics, increasing healthcare costs. The pan-Canadian Pharmaceutical Alliance, which negotiates drug prices, is impacted by the delayed approvals.

smh.com.au

🌐 85% Global Worthiness

Mar 23, 01:11

Australia's Slow Drug Subsidy Process Sparks US Trade Dispute

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays averaging 466 days for new drug subsidies, compared to 90 days in other countries, impacting patient access and drawing US trade concerns, prompting a government review with 50 recommendations for improvement.

Australia's Slow Drug Subsidy Process Sparks US Trade Dispute

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays averaging 466 days for new drug subsidies, compared to 90 days in other countries, impacting patient access and drawing US trade concerns, prompting a government review with 50 recommendations for improvement.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of Australia's slow approval process for new medicines under the PBS?

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays in subsidizing new medicines, averaging 466 days compared to 90 days in other countries. This impacts patient access to affordable treatments, with some forced to pay thousands for private options while waiting. The slow process has drawn US pharmaceutical complaints, raising trade dispute concerns.

zeit.de

🌐 75% Global Worthiness

Jul 19, 07:10

Boehringer CEO Calls for Faster Drug Approvals in Germany

Médard Schoenmaeckers, new Boehringer Ingelheim Germany CEO, criticizes slow drug approvals in Germany compared to the US, citing a three-year delay for a lung cancer drug currently in fast-track approval in the US. He also notes Germany's fall to seventh place globally in clinical trials and calls ...

Boehringer CEO Calls for Faster Drug Approvals in Germany

Médard Schoenmaeckers, new Boehringer Ingelheim Germany CEO, criticizes slow drug approvals in Germany compared to the US, citing a three-year delay for a lung cancer drug currently in fast-track approval in the US. He also notes Germany's fall to seventh place globally in clinical trials and calls ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the German pharmaceutical regulatory system compare to those of other leading countries, and what factors contribute to these differences?

Schoenmaeckers points to competition from countries like France and Spain with faster clinical trials and approvals, and the pressure from the US due to trade disputes and China's growing pharmaceutical presence. He stresses that Germany must become more competitive to retain investments and avoid negative consequences of a potential trade war, impacting industries like pharmaceuticals, automotive, and machinery.

Showing 1 to 3 of 3 results